Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07265271 · ClinicalTrials.gov registry record
A Cell-free tsRNA Signature for Early Detection of Hepatocellular Carcinoma
A clinical trial of Hepatocellular Carcinoma (HCC), sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT07265271 is a study of Hepatocellular Carcinoma (HCC) that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 600 participants, above the 311-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (93% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07265271, a study of Hepatocellular Carcinoma (HCC), is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited. This study seeks to develop a cell-free tsRNA (cf-tsRNA)-based liquid biopsy assay for accurate detection of early-stage HCC.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Small RNA sequence
- DIAGNOSTIC_TEST Rt-qPCR
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-01-15 |
| Est. Completion | 2026-06-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07265271
The ClinicalTrials.gov registry entry for NCT07265271 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 311-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (93% higher). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma (HCC) appearing as the primary indexed condition, and to 2 interventions - of which Small RNA sequence is the first listed.
NCT07265271 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07265271 about?
NCT07265271 is a clinical study titled "A Cell-free tsRNA Signature for Early Detection of Hepatocellular Carcinoma". Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited. This study seeks to develop a cell-free tsRNA (cf-tsRNA)-based liquid biopsy assay ...
What is the current status of trial NCT07265271?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2025-01-15. Estimated completion is 2026-06-18.
What conditions does trial NCT07265271 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma (HCC).
What interventions are being tested in trial NCT07265271?
The interventions under investigation include: Small RNA sequence (DIAGNOSTIC_TEST), Rt-qPCR (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07265271?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07265271 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma (HCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PSMA PET for the Staging and Management of Hepatocellular Carcinoma
RECRUITING
-
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
RECRUITING · Phase 1
-
The Dragon PLC Trial (DRAGON-PLC)
RECRUITING · NA
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
-
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.